3D Cell-Based Assays for Drug Screens: Challenges in Imaging, Image Analysis, and High-Content Analysis. (July 2019)

• Record Type: Journal Article
• Authors: Booij, Tijmen H.; Price, Leo S.; Danen, Erik H. J.
• Is Part Of: SLAS discovery. Volume 24:Number 6(2019)
• Page Start: 615
• Page End: 627
• Publication Date: 2019-07
• Subjects: high-content screening -- 3D culture -- imaging -- image analysis; ハイコンテントスクリーニング -- 三次元細胞培養 -- イメージング -- イメージアナリシス; 대용량 스크리닝 -- 3D 배양 -- 이미징 -- 이미지 분석; 关键词 高内涵筛选 -- 三维细胞培养 -- 成像 -- 图像分析; Drugs -- Analysis -- Periodicals; Drugs -- Testing -- Periodicals; Biomolecules -- Analysis -- Periodicals; Biomolecules -- Analysis; Drugs -- Analysis; Drugs -- Testing; Drug Evaluation, Preclinical; Molecular Biology -- methods; Periodicals; Periodicals; 615.1
• DOI: 10.1177/2472555219830087
• Languages: English
• ISSNs: 2472-5552

Abstract

The introduction of more relevant cell models in early preclinical drug discovery, combined with high-content imaging and automated analysis, is expected to increase the quality of compounds progressing to preclinical stages in the drug development pipeline. In this review we discuss the current switch to more relevant 3D cell culture models and associated challenges for high-throughput screening and high-content analysis. We propose that overcoming these challenges will enable front-loading the drug discovery pipeline with better biology, extracting the most from that biology, and, in general, improving translation between in vitro and in vivo models. This is expected to reduce the proportion of compounds that fail in vivo testing due to a lack of efficacy or to toxicity.